Flecainide and Antiarrhythmic Effects in a Mouse Model of Catecholaminergic Polymorphic Ventricular Tachycardia

Trends in Cardiovascular Medicine

Volumn 22, Issue 2, 2012, Pages 35-39

  Liu, Nian ^a   Napolitano, Carlo ^a,b   Venetucci, Luigi A ^b,c   Priori, Silvia G ^a,b,d  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b IRCCS   (Italy)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; CALSEQUESTRIN; FLECAINIDE; LIDOCAINE; PROPAFENONE; RYANODINE RECEPTOR; SODIUM CHANNEL; TETRACAINE;

ANTIARRHYTHMIC ACTIVITY; ARRHYTHMOGENESIS; CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; CONTINUOUS INFUSION; DRUG HALF LIFE; HEART ARRHYTHMIA; HEART MUSCLE CELL; HUMAN; IC 50; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; CATECHOLAMINES; DISEASE MODELS, ANIMAL; FLECAINIDE; MICE; MYOCYTES, CARDIAC; TACHYCARDIA, VENTRICULAR;

EID: 84866002959     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2012.06.008     Document Type: Review

References (29)

1. Barberini-Jammaers S., Silvester N., Gabriele Banci B., et al. Ouabain is a pharmacomimic of mutant RyR2 Ca2+ release dysfunction but is not a serum born trigger of CPVT. Biophys J 2011, 100:412a-413a.
2. Benowitz N.L., Meister W. Clinical pharmacokinetics of lignocaine. Clin Pharmacokinet 1978, 3:177-201.
3. Bers D.M. Cardiac excitation-contraction coupling. Nature 2002, 415:198-205.
4. Collinsworth K.A., Kalman S.M., Harrison D.C. The clinical pharmacology of lidocaine as an antiarrhythmic drug. Circulation 1974, 50:1217-1230.
5. 2+ waves in permeabilized myocytes lacking calsequestrin. J Mol Cell Cardiol 2011, 51:760-768.
6. Galimberti E.S., Knollmann B.C. "Use-dependent" block of ryanodine receptor calcium channels by flecainide and R-propafenone determines their potency for calcium wave annihilation in catecholaminergic polymorphic ventricular tachycardia. Circulation 2011, 124:A16336.
7. Györke S., Lukyanenko V., Györke I. Dual effects of tetracaine on spontaneous calcium release in rat ventricular myocytes. J Physiol 1997, 500(Pt 2):297-309.
8. 2+ spark mass. J Mol Cell Cardiol 2010, 48:293-301.
9. 2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia. Circ Arrhythm Electrophysiol 2011, 4:128-135.
10. Johnson J., Liggett S.B. Cardiovascular pharmacogenomics of adrenergic receptor signaling: Clinical implications and future directions. Clin Pharmacol Ther 2011, 89:366-378.
11. Kashimura T., Briston S.J., Trafford A.W., et al. In the RyR2(R4496C) mouse model of CPVT, beta-adrenergic stimulation induces Ca waves by increasing SR Ca content and not by decreasing the threshold for Ca waves. Circ Res 2011, 107:1483-1489.
12. Katz G., Khoury A., Kurtzwald E., et al. Optimizing catecholaminergic polymorphic ventricular tachycardia therapy in calsequestrin-mutant mice. Heart Rhythm 2010, 7:1676-1682.
13. Lahat H., Pras E., Olender T., et al. A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet 2001, 69:1378-1384.
14. Laitinen P.J., Brown K.M., Piippo K., et al. Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorphic ventricular tachycardia. Circulation 2001, 103:485-490.
15. Leenhardt A., Lucet V., Denjoy I., et al. Catecholaminergic polymorphic ventricular tachycardia in children: A 7-year follow-up of 21 patients. Circulation 1995, 91:1512-1519.
16. + channels: Evidence from experiments with neutral and quaternary flecainide analogues. J Gen Physiol 2003, 121:199-214.
17. Liu N., Colombi B., Memmi M., et al. Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia: Insights from a RyR2 R4496C knock-in mouse model. Circ Res 2006, 99:292-298.
18. Liu N., Denegri M., Ruan Y., et al. Short communication: Flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity. Circ Res 2011, 109:291-295.
19. Liu N., Rizzi N., Boveri L., Priori S.G. Ryanodine receptor and calsequestrin in arrhythmogenesis: What we have learnt from genetic diseases and transgenic mice. J Mol Cell Cardiol 2009, 46:149-159.
20. +/-) mice with catecholaminergic polymorphic ventricular tachycardia. J Mol Cell Cardiol 2011, 50:214-222.
21. 2+ handling and arrhythmogenesis. Circ Res 2011, 108:871-883.
22. Priori S.G., Napolitano C., Memmi M., et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 2002, 106:69-74.
23. Priori S.G., Napolitano C., Tiso N., et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 2001, 103:196-200.
24. Rizzi N., Liu N., Napolitano C., et al. Unexpected structural and functional consequences of the R33Q homozygous mutation in cardiac calsequestrin: A complex arrhythmogenic cascade in a knock in mouse model. Circ Res 2008, 103:298-306.
25. Uchinoumi H., Yano M., Suetomi T., et al. Catecholaminergic polymorphic ventricular tachycardia is caused by mutation-linked defective conformational regulation of the ryanodine receptor. Circ Res 2010, 106:1413-1424.
26. van der Werf C., Kannankeril P.J., Sacher F., et al. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol 2011, 57:2244-2254.
27. 2+ transient amplitude in adult ventricular myocytes. Circ Res 2006, 98:1299-1305.
28. Watanabe H., Chopra N., Laver D., et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med 2009, 15:380-383.
29. Watanabe H., Steele D.S., Knollmann B.C. Mechanism of antiarrhythmic effects of flecainide in catecholaminergic polymorphic ventricular tachycardia. Circ Res 2011, 109:712-713.